S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
Secure your stake in the Smart Home industry. (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Get ready for Christmas shopping-sprees with these 2 winners
Li Auto smashes estimates proving EVs can be profitable
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
Secure your stake in the Smart Home industry. (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Get ready for Christmas shopping-sprees with these 2 winners
Li Auto smashes estimates proving EVs can be profitable
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
Secure your stake in the Smart Home industry. (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Get ready for Christmas shopping-sprees with these 2 winners
Li Auto smashes estimates proving EVs can be profitable
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
Secure your stake in the Smart Home industry. (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Get ready for Christmas shopping-sprees with these 2 winners
Li Auto smashes estimates proving EVs can be profitable

Incyte Stock Price, News & Analysis (NASDAQ:INCY)

$52.70
-0.17 (-0.32%)
(As of 11/28/2023 ET)
Compare
Today's Range
$52.20
$52.79
50-Day Range
$52.16
$60.37
52-Week Range
$50.27
$86.29
Volume
1.76 million shs
Average Volume
1.74 million shs
Market Capitalization
$11.81 billion
P/E Ratio
27.88
Dividend Yield
N/A
Price Target
$79.94

Incyte MarketRank™ Stock Analysis

Analyst Rating
Hold
2.37 Rating Score
Upside/​Downside
51.7% Upside
$79.94 Price Target
Short Interest
Bearish
4.13% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.40
Upright™ Environmental Score
News Sentiment
-0.07mentions of Incyte in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
28.00%
From $3.00 to $3.84 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.75 out of 5 stars

Medical Sector

71st out of 949 stocks

Commercial Physical Research Industry

3rd out of 13 stocks


INCY stock logo

About Incyte Stock (NASDAQ:INCY)

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. The company offers JAKAFI (ruxolitinib), for the treatment of adults with intermediate or high-risk myelofibrosis; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include axatilimab, an anti-CSF-1R monoclonal antibody being developed as a therapy for patients with chronic GVHD as well as in additional immune-mediated diseases; and parsaclisib, a PI3Kd inhibitor which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It also develops retifanlimab, is in Phase III clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer, and Fast Track designation for the treatment of metastatic MSI-H or DNA mismatch repair (dMMR) endometrial cancer; and INCB99280 and INCB99318 currently under Phase I for the treatment solid tumors. It has collaboration out- license agreements with Novartis, Lilly, Innovent, InnoCare, Maruho, and CMS Aesthetics Limited; and in- license agreements with Agenus, Merus, MacroGenics, Syros, MorphoSys, and Syndax. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

INCY Stock Price History

INCY Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Goldman Sachs Downgrades Incyte (INCY)
Incyte (NASDAQ:INCY) Lowered to Neutral at The Goldman Sachs Group
Secure your stake in the Smart Home industry.
Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.
The Latest Analyst Ratings for Incyte
Stifel Nicolaus Keeps Their Hold Rating on Incyte (INCY)
TD Cowen Reaffirms Their Buy Rating on Incyte (INCY)
Incyte (INCY) Surpasses Q3 Earnings Estimates
See More Headlines
Receive INCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/31/2023
Today
11/28/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/06/2024

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:INCY
CUSIP
45337C10
Employees
2,324
Year Founded
1991

Price Target and Rating

Average Stock Price Target
$79.94
High Stock Price Target
$100.00
Low Stock Price Target
$61.00
Potential Upside/Downside
+51.7%
Consensus Rating
Hold
Rating Score (0-4)
2.37
Research Coverage
19 Analysts

Profitability

Net Income
$340.66 million
Pretax Margin
17.84%

Debt

Sales & Book Value

Annual Sales
$3.61 billion
Cash Flow
$2.39 per share
Book Value
$19.64 per share

Miscellaneous

Free Float
184,873,000
Market Cap
$11.81 billion
Optionable
Optionable
Beta
0.72

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives















INCY Stock Analysis - Frequently Asked Questions

Should I buy or sell Incyte stock right now?

19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last twelve months. There are currently 1 sell rating, 10 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" INCY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INCY, but not buy additional shares or sell existing shares.
View INCY analyst ratings
or view top-rated stocks.

What is Incyte's stock price target for 2024?

19 analysts have issued 12-month target prices for Incyte's shares. Their INCY share price targets range from $61.00 to $100.00. On average, they expect the company's share price to reach $79.94 in the next twelve months. This suggests a possible upside of 51.7% from the stock's current price.
View analysts price targets for INCY
or view top-rated stocks among Wall Street analysts.

How have INCY shares performed in 2023?

Incyte's stock was trading at $80.32 at the beginning of the year. Since then, INCY stock has decreased by 34.4% and is now trading at $52.70.
View the best growth stocks for 2023 here
.

When is Incyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 6th 2024.
View our INCY earnings forecast
.

How were Incyte's earnings last quarter?

Incyte Co. (NASDAQ:INCY) released its quarterly earnings data on Tuesday, October, 31st. The biopharmaceutical company reported $0.91 earnings per share for the quarter, hitting the consensus estimate of $0.91. The biopharmaceutical company earned $919.03 million during the quarter, compared to analysts' expectations of $973.32 million. Incyte had a net margin of 11.78% and a trailing twelve-month return on equity of 11.21%.

What is Hervé Hoppenot's approval rating as Incyte's CEO?

22 employees have rated Incyte Chief Executive Officer Hervé Hoppenot on Glassdoor.com. Hervé Hoppenot has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Incyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), (KITE) (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA).

Who are Incyte's major shareholders?

Incyte's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Invesco Ltd. (1.75%), Acadian Asset Management LLC (1.20%), Northern Trust Corp (0.95%), Morgan Stanley (0.95%), Jacobs Levy Equity Management Inc. (0.93%) and Legal & General Group Plc (0.78%). Insiders that own company stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Herve Hoppenot, Jonathan Elliott Dickinson, Maria E Pasquale, Michael James Morrissey, Paula J Swain, Steven H Stein, Thomas Tray, Vijay K Iyengar, Wendy L Dixon and Yao Wenqing.
View institutional ownership trends
.

How do I buy shares of Incyte?

Shares of INCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:INCY) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -